News
Subscribe to get the latest clinical and R&D news:
Press Releases and News Articles
- June 2022: Gradalis Appoints Steven Engle as Chief Executive Officer
- March 2022: Gradalis and University of Michigan collaboration to utilize a patient’s cancer cells to create personalized therapeutics to treat cancer
- March 2021: Phase 2b VITAL study of Gemogenovatucel-T (VigilTM) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer
- January 2021: Dr. Rod Rocconi on Med School Watercooler: Significant results for Ovarian Cancer Patients
- January 2021: Gradalis Announces Publication of Phase 2b VITAL trial of Vigil® demonstrating RFS and OS advantage in women with front-line platinum-responsive BRCA1 and BRCA2 wild-type advanced ovarian cancer
- December 2020: The Lancet Oncology: Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
- June 2020: Gradalis at ASCO Virtual Scientific Forum - Randomized double-blind placebo-controlled trial of primary maintenance GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.
- April 2020: Frontline Maintenance Vigil Immunotherapy Improves RFS in Ovarian Cancer
- June 2019: Exclusive: CBS DFW - Cancer Vaccine Developed In North Texas Could Be ‘As Simple As A Flu Shot’
- June 2019: Telemedicine: Catalyzing Cancer Care with Virtual Visits with Dr. Pete Anderson
- March 2019: Gradalis Announces Medical Leadership Team Promotion
- March 2019: Gradalis® Announces Initiation of Phase 3 Study of Vigil™ in Ewing’s sarcoma
- October 2018: Gradalis® Presents Initial Data from Phase II U.S. Trial forEwing’s sarcoma at the Annual Meeting of the Children’s Oncology Group
- August 2018: Gradalis® implements L7 Informatics’ Enterprise Science Platform as part of initiating Phase 3 Study of Vigil™ in Ewing’s sarcoma
